TOKYO--(BUSINESS WIRE)--Sosei Group Corporation (TOKYO:4565), the biopharmaceutical company, today announces that its Japanese subsidiary, Sosei Co., Ltd., (“Sosei K.K.”) has signed a distribution agreement for commercialization of SO-1105 in Japan with FUJIFILM Pharma Co., Ltd (“FUJIFILM Pharma”). SO-1105 is an antifungal agent, administered as a muco-adhesive buccal tablet for the treatment of oropharyngeal candidiasis in immunocompromised patients. It has the potential to become the first long-acting, sustained-release treatment in tablet form for oropharyngeal candidiasis in Japan that could enhance patients’ compliance and quality of life.
Help employers find you! Check out all the jobs and post your resume.
